CLC bio acquires the drug discovery-software company Molegro
CLC bio announced the acquisition of Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity. The acquisition of Molegro supports CLC bio's strategy of continuously expanding their bioinformatics offerings beyond Next Generation Sequencing, as well as in bioinformatics areas of value to their customer base.
"We have always had a strong focus on the science behind our software, and joining CLC bio allows us to become part of a strong analysis platform and focus even more on developing the next generation of molecular docking products." says CEO at Molegro, René Thomsen, PhD, and continues, "CLC bio has demonstrated the capability to build an elaborate analysis platform and distribute it internationally, and exactly that competence is the best way to take the features of Molegro's software to the next level."
Effective immediately, Molegro will become part of CLC bio's organization at their Aarhus, Denmark, headquarters. The financial terms of the transaction were not disclosed.
Other news from the department business & finance
